```
=> d his

     (FILE 'HOME' ENTERED AT 08:49:24 ON 15 FEB 2008)

     FILE 'REGISTRY' ENTERED AT 08:49:37 ON 15 FEB 2008
                E DONEPEZIL/CN
L1            1 S E3
                E CHLORPROMAZINE
                E CHLORPROMAZINE/CN
L2            1 S E3

     FILE 'CAPLUS' ENTERED AT 08:50:57 ON 15 FEB 2008
L3           31 S L1 AND L2
L4            3 S L3 AND PD<2002
```

=> d l4 ibib abs

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:319255 CAPLUS <<LOGINID::20080215>>
DOCUMENT NUMBER: 138:343854
TITLE: Buccal sprays or capsules containing drugs for treating disorders of the central nervous system
INVENTOR(S): Dugger, Harry A., III
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp., Cont.-in-part of U.S. Ser. No. 537,118.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 19
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003077227	A1	20030424	US 2002-230060	20020829
WO 9916417	A1	19990408	WO 1997-US17899	19971001 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
EP 1036561	A1	20000920	EP 2000-109357	19971001 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2497262	A1	20040429	CA 2003-2497262	20030827
WO 2004035021	A2	20040429	WO 2003-US26847	20030827
WO 2004035021	A3	20041111		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003298564	A1	20040504	AU 2003-298564	20030827
EP 1539106	A2	20050615	EP 2003-796314	20030827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505569	T	20060216	JP 2004-545251	20030827
US 2004141923	A1	20040722	US 2003-671720	20030929
US 2004265239	A1	20041230	US 2003-671715	20030929
US 2005163719	A1	20050728	US 2003-671709	20030929
US 2004120895	A1	20040624	US 2003-726585	20031204
US 6977070	B2	20051220		

US 2005002867	A1	20050106	US 2004-834815		20040427
US 2006159624	A1	20060720	US 2006-384444		20060321
US 2006171896	A1	20060803	US 2006-391297		20060329
US 2006222597	A1	20061005	US 2006-442137		20060530
US 2006216240	A1	20060928	US 2006-443253		20060531
US 2006216241	A1	20060928	US 2006-443254		20060531
PRIORITY APPLN. INFO.:			WO 1997-US17899	A2	19971001
			US 2000-537118	A2	20000329
			EP 1997-911621	A3	19971001
			US 2002-230060	A	20020829
			WO 2003-US26847	W	20030827
			US 2003-671709	A3	20030929
			US 2003-671715	A3	20030929
			US 2003-671720	A3	20030929
			US 2004-834815	A3	20040427

AB Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biol. active compds. for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compns. of the invention comprise formulation A: aqueous polar solvent, active compound, and optional flavoring agent; formulation B: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation C: non-polar solvent, active compound, and optional flavoring agent; and formulation D: non-polar solvent, active compound, optional flavoring agent, and propellant. Thus, a lingual spray contained sumatriptan succinate 10-15, EtOH 10-20, propylene glycol 10-15, PEG 35-40, water 10-15, and flavors 2-3%.

=> d ibib abs 2-3

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:725436 CAPLUS <<LOGINID::20080215>>
DOCUMENT NUMBER: 133:301171
TITLE: Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
INVENTOR(S): Chen, Feng-jing; Patel, Manesh V.
PATENT ASSIGNEE(S): Lipocine, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059475	A1	20001012	WO 2000-US7342	20000316 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6383471	B1	20020507	US 1999-287043	19990406

CA 2366702	A1	20001012	CA 2000-2366702	20000316 <--
EP 1165048	A1	20020102	EP 2000-916547	20000316

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO

PRIORITY APPLN. INFO.: US 1999-287043 A 19990406
WO 2000-US7342 W 20000316

AB The present invention is directed to a pharmaceutical composition including a hydrophobic therapeutic agent having at least one ionizable functional group, and a carrier. The carrier includes an ionizing agent capable of ionizing the functional group, a surfactant, and optionally solubilizers, triglycerides, and neutralizing agents. The invention further relates to a method of preparing such compns. by providing a composition of an ionizable hydrophobic therapeutic agent, an ionizing agent, and a surfactant, and neutralizing a portion of the ionizing agent with a neutralizing agent. The compns. of the invention are particularly suitable for use in oral dosage forms. A carrier containing concentrated phosphoric acid 0.025, Tween-20 0.3, Arlacel 186 0.2, sodium taurocholate 0.15, propylene glycol 0.3 g was formulated. Itraconazole was included in the carrier at 30 mg/mL for testing the stability of the itraconazole solution upon dilution in simulated gastric fluid.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:672562 CAPLUS <<LOGINID::20080215>>
DOCUMENT NUMBER: 131:281590
TITLE: Methods for treating neuropsychiatric disorders
INVENTOR(S): Tsai, Guochuan; Coyle, Joseph
PATENT ASSIGNEE(S): The General Hospital Corporation, USA
SOURCE: PCT Int. Appl., 27 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9952519	A2	19991021	WO 1999-US8056	19990414 <--
WO 9952519	A3	19991202		

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2328197	A1	19991021	CA 1999-2328197	19990414 <--
CA 2328197	C	20071120		
CA 2601132	A1	19991021	CA 1999-2601132	19990414 <--
AU 9935571	A	19991101	AU 1999-35571	19990414 <--
AU 765603	B2	20030925		
EP 1073432	A2	20010207	EP 1999-917453	19990414 <--
EP 1073432	B1	20070815		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY

US 6228875	B1	20010508	US 1999-291296	19990414	<--
HU 2001001627	A2	20011028	HU 2001-1627	19990414	<--
HU 2001001627	A3	20030228			
JP 2002511409	T	20020416	JP 2000-543129	19990414	
RU 2219924	C2	20031227	RU 2000-128654	19990414	
NZ 508160	A	20040130	NZ 1999-508160	19990414	
AT 369848	T	20070915	AT 1999-917453	19990414	
EP 1844769	A2	20071017	EP 2007-75595	19990414	

R: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE

ES 2164040	T3	20080201	ES 1999-917453	19990414	
MX 2000PA10009	A	20010521	MX 2000-PA10009	20001013	<--
US 2002035145	A1	20020321	US 2001-834351	20010413	
US 6420351	B2	20020716			
US 2002193429	A1	20021219	US 2002-196686	20020715	
US 6667297	B2	20031223			
US 2004092530	A1	20040513	US 2003-668583	20030923	
US 6974821	B2	20051213			
US 2005250851	A1	20051110	US 2005-175832	20050705	

PRIORITY APPLN. INFO.:

US 1998-81645P	P	19980414
CA 1999-2328197	A3	19990414
EP 1999-917453	A3	19990414
US 1999-291296	A1	19990414
WO 1999-US8056	W	19990414
US 2001-834351	A1	20010413
US 2002-196686	A1	20020715
US 2003-668583	A1	20030923

AB The invention provides methods for treating neuropsychiatric disorders such as schizophrenia, Alzheimer's Disease, autism, depression, benign forgetfulness, childhood learning disorders, close head injury, and attention deficit disorder. The methods entail administering to a patient with a neuropsychiatric disorder a pharmaceutical composition containing (i) a therapeutically effective amount of D-alanine (or a modified form), provided that the composition is substantially free of D-cycloserine, and/or (ii) D-serine (or a modified form), and/or (iii) 105 to 500 mg of D-cycloserine (or a modified form), and/or (iv) N-methylglycine (or a modified form). Using double-blind conditions, patients were randomly assigned to receive placebo (fruit juice), D-serine 30, D-alanine 60-100, or N-methylglycine 30 mg/kg/day once a day by mouth for 6 wk. Treatment with D-serine, D-alanine, or N-methylglycine improved the schizophrenic symptoms and cognitive deficit of the patients. Specifically, treatment with D-serine resulted in a 21% reduction of the neg. symptoms (on the SANS scale), and it resulted in a 17% reduction of the pos. symptoms. Treatment with D-alanine resulted in an 11% reduction of the neg. symptoms and a 12% reduction of the pos.
symptoms. Reatment with N-methylglycine resulted in a 20% reduction of the neg. symptoms and a 15% reduction of the pos. symptoms. These redns. in the neg. and pos. symptoms represented clin. significant improvement.

```
=> s e3
L2            1 CHLORPROMAZINE/CN

=> d

L2   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   50-53-3  REGISTRY
ED   Entered STN:  16 Nov 1984
CN   10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl-  (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN   Phenothiazine, 2-chloro-10-[3-(dimethylamino)propyl]- (7CI, 8CI)
OTHER NAMES:
CN   2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine
CN   2-Chloropromazine
CN   2601A
CN   Aminazin
CN   Aminazine
CN   Ampliactil
CN   Amplictil
CN   BC 135
CN   Chlor-Promanyl
CN   Chlordelazin
CN   Chlorderazin
CN   Chlorpromados
CN   Chlorpromazine
CN   Chlropromados
CN   Contomin
CN   CPZ
CN   Elmarin
CN   Esmind
CN   Fenactil
CN   Fenaktyl
CN   Fraction AB
CN   HL 5746
CN   Largactilothiazine
CN   Largactyl
CN   Megaphen
CN   Noiafren
CN   Novomazina
CN   NSC 167745
CN   NSC 226514
CN   Phenactyl
CN   Proma
CN   Promactil
CN   Promazil
CN   Propaphenin
CN   Prozil
CN   RP 4560
CN   Sanopron
CN   Sedatil
CN   SKF 2601A
CN   Thorazin
CN   Thorazine
CN   Wintermin
MF   C17 H19 Cl N2 S
```

CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH, IMSDRUGNEWS, IPA, MEDLINE, MRCK*, PIRA, PROMT, PROUSDDR, PS, RTECS*, SCISEARCH, SPECINFO, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL, USPATOLD, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



```
=> s e3
L1            1 DONEPEZIL/CN

=> d

L1   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   120014-06-4  REGISTRY
ED   Entered STN:  07 Apr 1989
CN   1H-Inden-1-one, 2,3-dihydro-5,6-dimethoxy-2-[[1-(phenylmethyl)-4-
     piperidinyl]methyl]-  (CA INDEX NAME)
OTHER NAMES:
CN   (±)-E 2020
CN   1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine
CN   Donepezil
DR   142057-79-2
MF   C24 H29 N O3
CI   COM
SR   CA
LC   STN Files:   ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOSIS, BIOTECHNO,
       CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, CSNB, DDFU, DRUGU,
       EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK*, MSDS-OHS,
       PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER,
       USAN, USPAT2, USPATFULL
         (*File contains numerically searchable property data)
     Other Sources:   WHO
```